secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-023839
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Q3 revenue $0.5M, net loss $25.7M; cash $239M covers into H1 2025; 4D-710 CF data positive
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities totaled $239M; runway into first half of 2025.
- Revenue $0.5M (down from $1.4M), net loss $25.7M vs $22.2M, R&D $18.9M.
- Interim Phase 1/2 data for 4D-710 CF: no drug-related adverse events, widespread transgene expression in all lung samples.
- Clinical progress highlighted across 4D-150, 4D-310, and 4D-710 programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017022023839/0000950170-22-023839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017022023839/fdmt-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer